Praxis Precision Medicines, Inc.
HealthcareNASDAQ:PRAX · NASDAQ Global Select
+$18.60 today
Vol 0.42M · Avg 0.44M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-34.5%
avg -111.4%
ROIC
-37.1%
avg -105.6%
ROA
-32.3%
avg -85.2%
Analysis
ROA is currently the strongest return metric at -32.3% versus its period average of -85.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Marcio Souza | President, Chief Executive Officer & Director | $2.65M | — | 47 | $77,016.00 | 0.36% |
Timothy Edwin Kelly | Chief Financial Officer & Treasurer | $1.18M | — | 53 | $31,167.00 | 0.15% |
Alex Nemiroff | General Counsel & Secretary | $1.03M | — | 47 | $26,010.67 | 0.12% |
Karl Hansen | Chief Technical Operations Officer | — | — | — | — | — |
Brian Spar | Chief of Staff | — | — | — | — | — |
Alyssa J. S. Wyant | Chief Regulatory & Quality Officer | — | — | 51 | — | — |
Megan T. Sniecinski | Chief Operating Officer | — | — | 45 | $28,664.00 | 0.14% |
Orrin Devinsky | Head of Clinical Strategy | — | — | 68 | — | — |
Steven Petrou | Co-Founder and President of Research & Development | — | — | — | — | — |
Kelly McCue | Chief People Officer | — | — | — | $31,167.00 | 0.15% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
10
$33.20M
Sells
6
$7.46M
Net Sentiment
+$25.73M
Net buying
Most Active
Adage Capital Management, L.P.
10 transactions
1–10 of 16
Analysis
Insiders reported 10 buys worth $33.20M and 6 sells worth $7.46M over the last 12 months. That adds up to net buying of $25.73M. Adage Capital Management, L.P. was the most active insider with 10 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Immunovant, Inc.
NASDAQ:IMVT
$6.90B
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.15B
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.12B
Akero Therapeutics, Inc.
AKRO
$4.50B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.11B
Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX
$3.63B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.61B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.34B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Who manages PRAX?
Praxis Precision Medicines, Inc. (PRAX) lists 10 active executives. The top listed executive is Karl Hansen, Chief Technical Operations Officer.
Are PRAX insiders buying or selling?
Recent insider activity shows net buying of $74.42M.
Explore More
Continue the stock analysis
Jump to another research area for this company.